rs11542065
Variant summary
Our verdict is Benign. Variant got -16 ACMG points: 0P and 16B. BP4_StrongBP6_Very_StrongBS2
The NM_000237.3(LPL):āc.213C>Gā(p.His71Gln) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000596 in 1,614,130 control chromosomes in the GnomAD database, including 3 homozygotes. In-silico tool predicts a benign outcome for this variant. 14/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (ā ā ). Synonymous variant affecting the same amino acid position (i.e. H71H) has been classified as Benign.
Frequency
Consequence
NM_000237.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
LPL | NM_000237.3 | c.213C>G | p.His71Gln | missense_variant | 2/10 | ENST00000650287.1 | NP_000228.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
LPL | ENST00000650287.1 | c.213C>G | p.His71Gln | missense_variant | 2/10 | NM_000237.3 | ENSP00000497642 | P1 |
Frequencies
GnomAD3 genomes AF: 0.00331 AC: 503AN: 152156Hom.: 1 Cov.: 31
GnomAD3 exomes AF: 0.000839 AC: 211AN: 251448Hom.: 0 AF XY: 0.000677 AC XY: 92AN XY: 135892
GnomAD4 exome AF: 0.000313 AC: 458AN: 1461856Hom.: 2 Cov.: 31 AF XY: 0.000285 AC XY: 207AN XY: 727230
GnomAD4 genome AF: 0.00331 AC: 504AN: 152274Hom.: 1 Cov.: 31 AF XY: 0.00352 AC XY: 262AN XY: 74460
ClinVar
Submissions by phenotype
not provided Benign:2
Benign, criteria provided, single submitter | clinical testing | GeneDx | Mar 22, 2021 | This variant is associated with the following publications: (PMID: 33303402, 22129523) - |
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 29, 2024 | - - |
not specified Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Aug 05, 2024 | Variant summary: LPL c.213C>G (p.His71Gln) results in a non-conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00084 in 251790 control chromosomes, predominantly at a frequency of 0.013 within the African or African-American subpopulation in the gnomAD database. The observed variant frequency within African or African-American control individuals in the gnomAD database is approximately 4 fold of the estimated maximal expected allele frequency for a pathogenic variant in LPL causing Familial Lipoprotein Lipase Deficiency phenotype (0.0034). one study identified the variant in 9 of 208 patients with familial hyperlipidemia but did not detect the variant in 171 control individuals, revealing an enrichment of the variant in patients (odds ratio of 16.33 [95% CI = 0.94 - 282.7], Minicocci_2015)(As calculated using the online OR calculator tool, MEDCALC using the case controls data published in Minicocci_Athero_2015). As the 95% CI overlaps 1 there is little confidence in the strength of this assertion and additional large studies would be needed to validate this finding. This variant was also reported in two more individuals from a cohort of hypertriglyceridemia, without primary information (Deshotels_2022). These report(s) do not provide unequivocal conclusions about association of the variant with Familial Lipoprotein Lipase Deficiency. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 36325899, 26342331). ClinVar contains an entry for this variant (Variation ID: 495743). Based on the evidence outlined above, the variant was classified as likely benign. - |
Hyperlipoproteinemia, type I Benign:1
Likely benign, no assertion criteria provided | clinical testing | Natera, Inc. | Jan 10, 2020 | - - |
LPL-related disorder Benign:1
Benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Dec 06, 2019 | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at